Roche calls on AnaptysBio for antibody development
Roche has received global rights to develop and sell novel antibodies identified and optimized by AnaptysBio (specializes in somatic hypermutation of therapeutic antibodies).
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.